Agreement for chimeras technoloy platform

0

Arvinas entered into a license agreement with Genentech (member of Roche group) for the development of new therapeutics using Arvinas’ novel PROTAC technology. Proteolysis-targeting chimeras (PROTACs), are bifunctional small molecules designed to target proteins for degradation and removal from a cell. These molecules are intended to induce a cell’s own protein-degradation machinery to bind to a particular protein and “label” it for degradation, thus removing that protein from the system entirely. Arvinas’ approach has the potential to radically expand the number of disease-causing proteins that can be targeted. Full financial terms of the agreement have not been disclosed

 

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here